Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed May 10, 2019 21:00 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000031 · primary_doc.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,709.8535 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:25 UTC |
SELLERS ROBERT W.A.VP, Corp. Controller (Principa
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 2,410 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000029 · primary_doc.xml · derivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corp. Controller (Principa 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410 Underlying: Common Stock · 2,410 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:25 UTC |
SELLERS ROBERT W.A.VP, Corp. Controller (Principa
|
GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000029 · primary_doc.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corp. Controller (Principa 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,674.9846 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 19:10 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantPerformance Rights · Derivative | 2,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000028 · primary_doc.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 Underlying: Common Stock · 2,325 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 19:10 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 16,400 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000028 · primary_doc.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 19:10 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000028 · primary_doc.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,207.5729 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 18:18 UTC |
Ullem Scott B.CVP, CFO
|
GrantPerformance Rights · Derivative | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000027 · primary_doc.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825 Underlying: Common Stock · 2,825 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 18:18 UTC |
Ullem Scott B.CVP, CFO
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 19,900 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000027 · primary_doc.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Underlying: Common Stock · 19,900 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 18:18 UTC |
Ullem Scott B.CVP, CFO
|
GrantCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000027 · primary_doc.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,626 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:54 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
GrantPerformance Rights · Derivative | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000026 · primary_doc.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 1,625 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · balance_after: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:54 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 11,500 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000026 · primary_doc.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:54 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000026 · primary_doc.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,509 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:35 UTC |
WANG HUIMINCVP, Japan & International
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001510192-19-000052 · primary_doc.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,850 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:35 UTC |
WANG HUIMINCVP, Japan & International
|
SaleCommon Stock | 4,650 | $176.17 | $819,190.50 |
DisclosureSEC source: 0001510192-19-000052 · primary_doc.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,321.1557 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:35 UTC |
WANG HUIMINCVP, Japan & International
|
Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001510192-19-000052 · primary_doc.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,971.1557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:25 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Ameri
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,188 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001510192-19-000051 · primary_doc.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Ameri 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,188 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:25 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Ameri
|
SaleCommon Stock | 4,188 | $176.17 | $737,799.96 |
DisclosureSEC source: 0001510192-19-000051 · primary_doc.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Ameri 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,409.8535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:25 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Ameri
|
Exercise / conversionCommon Stock | 4,188 | $42.73 | $178,932.30 |
DisclosureSEC source: 0001510192-19-000051 · primary_doc.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Ameri 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,597.8535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 01, 2019 Filed May 1, 2019 22:58 UTC |
Wood Larry LCVP, TAVR
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-007509 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,020 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| May 01, 2019 Filed May 1, 2019 22:58 UTC |
Wood Larry LCVP, TAVR
|
SaleCommon Stock | 6,716 | $176.34 | $1,184,299.44 |
DisclosureSEC source: 0001225208-19-007509 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,778.9386 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| May 01, 2019 Filed May 1, 2019 22:58 UTC |
Wood Larry LCVP, TAVR
|
Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-007509 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,494.9386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:06 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,800 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-007347 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,000 Underlying: Common Stock · 32,800 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:06 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 16,975 | $174.79 | $2,966,997.44 |
DisclosureSEC source: 0001225208-19-007347 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,125.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $174.3900 to $175.3850. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:06 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 10,425 | $174.17 | $1,815,675.34 |
DisclosureSEC source: 0001225208-19-007347 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,100.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $173.3900 to $174.3800. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:06 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 5,400 | $175.67 | $948,619.08 |
DisclosureSEC source: 0001225208-19-007347 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,525.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $175.3900 to $176.0600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:06 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 32,800 | $35.79 | $1,173,748.00 |
DisclosureSEC source: 0001225208-19-007347 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,925.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. Read SEC document |
| April 26, 2019 Filed Apr 26, 2019 23:06 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 821 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-007240 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 821 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2019 Filed Apr 26, 2019 23:06 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
SaleCommon Stock | 821 | $175.36 | $143,970.56 |
DisclosureSEC source: 0001225208-19-007240 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,354.9846 Read SEC document |
| April 26, 2019 Filed Apr 26, 2019 23:06 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
Exercise / conversionCommon Stock | 821 | $42.73 | $35,077.23 |
DisclosureSEC source: 0001225208-19-007240 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,175.9846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 14:57 UTC |
Szyman Catherine M.CVP, Critical Care
|
SaleCommon Stock | 328 | $192.00 | $62,976.00 |
DisclosureSEC source: 0001225208-19-006805 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,646 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 14:57 UTC |
Szyman Catherine M.CVP, Critical Care
|
SaleCommon Stock | 774 | $192.00 | $148,608.00 |
DisclosureSEC source: 0001225208-19-006805 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,357.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 14:57 UTC |
Szyman Catherine M.CVP, Critical Care
|
SaleCommon Stock | 372 | $192.00 | $71,424.00 |
DisclosureSEC source: 0001225208-19-006805 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 22:34 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-006616 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 22:34 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
SaleCommon Stock | 300 | $189.95 | $56,985.00 |
DisclosureSEC source: 0001225208-19-006616 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,115.3275 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 22:34 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 300 | $42.73 | $12,817.50 |
DisclosureSEC source: 0001225208-19-006616 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,415.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 19:09 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,186 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-006591 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,188 Underlying: Common Stock · 4,186 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 19:09 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
SaleCommon Stock | 4,186 | $188.23 | $787,930.78 |
DisclosureSEC source: 0001225208-19-006591 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,409.8535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 19:09 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
Exercise / conversionCommon Stock | 4,186 | $42.73 | $178,846.85 |
DisclosureSEC source: 0001225208-19-006591 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,595.8535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 23:10 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-006513 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 23:10 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
SaleCommon Stock | 4,650 | $189.31 | $880,291.50 |
DisclosureSEC source: 0001225208-19-006513 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,321.1557 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 23:10 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-006513 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,971.1557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 01, 2019 Filed Apr 1, 2019 21:23 UTC |
Wood Larry LCVP, TAVR
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-005950 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,736 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| April 01, 2019 Filed Apr 1, 2019 21:23 UTC |
Wood Larry LCVP, TAVR
|
SaleCommon Stock | 6,716 | $192.34 | $1,291,744.69 |
DisclosureSEC source: 0001225208-19-005950 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,778.9386 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| April 01, 2019 Filed Apr 1, 2019 21:23 UTC |
Wood Larry LCVP, TAVR
|
Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-005950 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,494.9386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,186 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-005776 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,374 Underlying: Common Stock · 4,186 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
SaleCommon Stock | 4,186 | $188.60 | $789,479.60 |
DisclosureSEC source: 0001225208-19-005776 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,409.8535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
Exercise / conversionCommon Stock | 4,186 | $42.73 | $178,846.85 |
DisclosureSEC source: 0001225208-19-005776 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,595.8535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-005775 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,150 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
SaleCommon Stock | 4,650 | $188.60 | $876,990.00 |
DisclosureSEC source: 0001225208-19-005775 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,224.3906 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-005775 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,874.3906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.